Hymeglusin (L-659,699) is the specific HMGCS1 inhibitor [20], and hymeglusin enhances the therapeutic efficacy of venetoclax in acute myeloid leukemia [21]. This evidence concerns the gene HMGCS1 and acute myeloid leukemia.